drugset / Trial / NCT02575807
Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This 2-part, Phase 1/2 study will test investigational cancer drugs known as CRS-207, epacadostat (IDO), and pembrolizumab (pembro). The purpose of this study is to find out how safe it is to give the investigational drugs to women with platinum-resistant ovarian, fallopian tube, or peritoneal cancer and if it helps patients with these types of cancer live longer or can help shrink or slow the growth of cancer.
Timeline
- Start
- 2016-03-08
- Primary completion
- 2018-04-26
- Completion
- 2018-05-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CRS-207 | Vaccine | 1e+09 unknown | Intravenous |
| Subject | Epacadostat | Small molecule | 100 mg | Oral |
| Subject | Epacadostat | Small molecule | 300 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |